Semaglutide, commonly known by brand names like Ozempic and WeGovy, is a medication that was originally designed to help people living with type 2 diabetes mellitus
For individuals with obesity and comorbid psychological symptoms, combined outcomes such as clinically significant weight loss (e.g., 10%) and reduced binge-eating frequency or depressive symptoms are reasonable targets
Semaglutide FDA-approved uses for each brand are Ozempic (type 2 diabetes, reducing cardiovascular event risks, reducing risk of kidney function decline), Wegovy (weight management, reducing cardiovascular event risks, non-cirrhotic MASH), and Rybelsus (type 2 diabetes, reducing cardiovascular event risks)
Details of clinical codes for eligibility criteria, exposure, outcomes, and confounders are in Supplementary Table S1 in the Supplementary Appendix
Failing to do so could put the patients health at risk
Participants who began at lower doses and increased incrementally reported better tolerability than those who escalated more rapidly